Evidence map›Paper›PMID 22899170›Full record

ArticleBasic research in cardiology2012

Secretome of apoptotic peripheral blood cells (APOSEC) attenuates microvascular obstruction in a porcine closed chest reperfused acute myocardial infarction model: role of platelet aggregation and vasodilation.

K Hoetzenecker, A Assinger, M Lichtenauer, M Mildner, T Schweiger, P Starlinger, A Jakab, E Berényi, N Pavo, M Zimmermann and 5 more

Open access · hybridAbstract read
In one paragraph

Article in Basic research in cardiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 42 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Quantitative Hybrid Cardiac [Molecular therapy. Methods & clinical development · 2020
    Article
  12. Article
  13. Article
  14. Article
  15. Peripheral blood mononuclear cell secretome for tissue repair.Apoptosis : an international journal on programmed cell death · 2016
    Review
  16. Dying blood mononuclear cell secretome exerts antimicrobial activity.European journal of clinical investigation · 2016
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

K HoetzeneckerDepartment of Thoracic Surgery, Medical University of Vienna, Vienna, Austria.
A Assinger
M Lichtenauer
M Mildner
T Schweiger
P Starlinger
A Jakab
E Berényi
N Pavo
M Zimmermann
C Gabriel
C Plass
M Gyöngyösi
I Volf
H J Ankersmit
Medical University of Vienna · ATUniversity of Debrecen · HUAustrian Red Cross · ATChristian Doppler Laboratory for Thermoelectricity · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although epicardial blood flow can be restored by an early intervention in most cases, a lack of adequate reperfusion at the microvascular level is often a limiting prognostic factor of acute myocardial infarction (AMI). Our group has recently found that paracrine factors secreted from apoptotic peripheral blood mononuclear cells (APOSEC) attenuate the extent of myocardial injury. The aim of this study was to determine the influence of APOSEC on microvascular obstruction (MVO) in a porcine AMI model. A single dose of APOSEC was intravenously injected in a closed chest reperfused infarction model. MVO was determined by magnetic resonance imaging and cardiac catheterization. Role of platelet function and vasodilation were monitored by means of ELISA, flow cytometry, aggregometry, western blot and myographic experiments in vitro and in vivo. Treatment of AMI with APOSEC resulted in a significant reduction of MVO. Platelet activation markers were reduced in plasma samples obtained during AMI, suggesting an anti-aggregatory capacity of APOSEC. This finding was confirmed by in vitro tests showing that activation and aggregation of both porcine and human platelets were significantly impaired by co-incubation with APOSEC, paralleled by vasodilator-stimulated phosphoprotein (VASP)-mediated inhibition of platelets. In addition, APOSEC evidenced a significant vasodilatory capacity on coronary arteries via p-eNOS and iNOS activation. Our data give first evidence that APOSEC reduces the extent of MVO during AMI, and suggest that modulation of platelet activation and vasodilation in the initial phase after myocardial infarction contributes to the improved long-term outcome in APOSEC treated animals.

Indexed as

Platelet AggregationVasodilationAnimalsCell Adhesion MoleculesCells, CulturedDisease Models, AnimalHumansIn Vitro TechniquesLeukocytes, MononuclearMicrofilament ProteinsMyocardial InfarctionPhosphoproteinsPlatelet ActivationSwineVasodilator-Stimulated PhosphoproteinCell Adhesion MoleculesMicrofilament ProteinsPhosphoproteinsVasodilator-Stimulated Phosphoprotein

Identifiers

PMID22899170
PMCPMC3442164
OpenAlexW2089300809

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.